Rep. John Moolenaar Asks Why NIH Leaders are Allowed to Discourage Use of Off-Patent Drugs While Collecting Royalties on New Products
“What strikes me is you’re in a position where you say certain drugs don’t work, but then you can at the same time be getting royalties from other products.”
*From the 2023 NIH Budget Hearing in May 2022
https://twitter.com/thechiefnerd/status/1689649894410305536
@ChiefNerd
Post #7978
31.1K
- 🔥 638
- 👍 98
- 🤬 50
- 🏆 24
- 🤡 13
- ❤ 12
- 🤮 1